这是一项第二期／第三期随机临床试验，评估放射敏感性辅助个人化自适应放射治疗技术（RAPART）在局部晚期非小细胞肺癌患者中的应用。主要目标是测试在标准与非标准混合治疗条件下，不可切除的第三期NSCLC相比于传统治疗在总生存期（OS）、无进展生存期（PFS）及局部无进展生存期（LPFS）的整体改善。
适应症：Locally Advanced Non-small Cell Lung Cancer
入组条件
纳入标准
- Adult research participants, aged over 18 years old;
- Non small cell lung cancer that requires pathological confirmation;
- All stage 3 unresectable non-small cell lung cancer, including stage correction after MDT and stage downgrading after treatment (4 → 3), and stage upregulation due to disease progression (2 → 3);
- ECOG physical condition is 0-2;
- In addition to study participants who have not received any treatment, study participants who have undergone surgery, chemotherapy, immunotherapy, and targeted therapy are also eligible for enrollment.
排除标准
- Prisoners who are not convenient for close clinical follow-up;
- Study participants with contraindications to radiation therapy.
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。